Gene Therapy Patient Engagement, March 23-25, 2021

Despite unprecedented investment in the field, engaging patients and building clinical programs with patients at the center remains the critical factor in achieving success in the gene therapy space.

In this context, the inaugural Gene Therapy Patient Engagement Summit will delve into the specific details of how to integrate the patient voice at every stage of gene therapy development, enabling you to collaborate with the patient community more effectively than ever before.

By leveraging knowledge and experience from patient advocacy leaders at gene therapy companies, patient advocacy organizations and patients themselves, this digital meeting will probe a level beyond broad concepts and explore case studies on defining novel outcomes for gene therapy trials, managing the unique challenges involved in long-term follow-ups and when, how and with which tools to engage patients most effectively.

Join this definitive, digital conference to hear directly from companies and institutions who are sharing real-world examples of what (and what hasn’t) been successful in integrating the patient voice in gene therapy to gain actionable insights that will strengthen your own pipeline development.

Tickets https://go.evvnt.com/713882-1?pid=176 
Brochure https://go.evvnt.com/713882-3?pid=176 

Prices:
Conference Only - Industry Rate - Early Booking Price USD 1699.00
Conference Only - Discounted Rate - Early Booking Price USD 1499.00
Conference Only - Industry Rate - Final Price USD 1999.00
Conference Only - Discounted Rate - Final Price USD 1799.00

Speakers: Kyle Bryant, Friedreich’s Ataxia Research Alliance (FARA), Daniel Leonard, uniQure, Susan Walther, Friedreich’s Ataxia Research Alliance (FARA), Fernanda Copeland, AVROBIO, Karen Jackler, FDA, Christian Rubio, Global Genes, Danielle Boyce, NORD, Allyson Berent, FAST, Edgar Vega, uniQure, Brian Robinson, Freeline Therapeutics, Paula Evans, FAST, Nita Patel, Amicus Therapeutics, Magali Taiel, GenSight Biologics, Tom Pulles, Ultragenyx, Samantha Parker, Lysogene, Christeen Moburg, Sangamo Therapeutics, Emily McGinnis, Taysha Gene Therapies, Linda Lowes, Nationwide Children’s Hospital, Nicolas Garnier, Pfizer, Sarah Friedhoff, Abeona Therapeutics, Erin Frey, CureDuchenne, Emily Fields, bluebird bio, Nan Doyle, Takeda, Anne Rowzee, FDA, Jill Dolgin, AGTC, Tom Croce, bluebird bio, Tiffany Cook, CureDuchenne Cares, Kyle Bryant Friedreich’s Ataxia Research Alliance (FARA)

Time: on Tuesday March 23, 2021 at 8:00 am (ends Thursday March 25, 2021 at 5:00 pm)